Regenerx Biopharm In Stock Probability Of Bankruptcy
| RGRXDelisted Stock | USD 0.03 0.01 25.00% |
Regenerx |
Regenerx Biopharm In OTC Stock probability of bankruptcy Analysis
Regenerx Biopharm's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Regenerx Biopharm Probability Of Bankruptcy | Over 100% |
Most of Regenerx Biopharm's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Regenerx Biopharm In is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Regenerx Biopharm probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Regenerx Biopharm odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Regenerx Biopharm In financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Regenerx Biopharm In has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Biotechnology sector and 82.35% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Regenerx Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regenerx Biopharm's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Regenerx Biopharm could also be used in its relative valuation, which is a method of valuing Regenerx Biopharm by comparing valuation metrics of similar companies.Regenerx Biopharm is currently under evaluation in probability of bankruptcy category among its peers.
Regenerx Fundamentals
| Return On Asset | -0.84 | ||||
| Operating Margin | (19.03) % | ||||
| Current Valuation | 22.91 M | ||||
| Shares Outstanding | 143.55 M | ||||
| Shares Owned By Insiders | 45.99 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 19.19 K | ||||
| Price To Earning | 17.73 X | ||||
| Price To Sales | 261.81 X | ||||
| Revenue | 76.76 K | ||||
| Gross Profit | 70.12 K | ||||
| EBITDA | (1.27 M) | ||||
| Net Income | (1.6 M) | ||||
| Cash And Equivalents | 478.41 K | ||||
| Total Debt | 1.14 M | ||||
| Current Ratio | 1.05 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (990.3 K) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 1.5 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 20.1 M | ||||
| Total Asset | 1.28 M | ||||
| Retained Earnings | (105.27 M) | ||||
| Working Capital | 806 K | ||||
| Current Asset | 1.19 M | ||||
| Current Liabilities | 382 K | ||||
| Net Asset | 1.28 M |
About Regenerx Biopharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regenerx Biopharm In's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regenerx Biopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regenerx Biopharm In based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in Regenerx OTC Stock
If you are still planning to invest in Regenerx Biopharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Regenerx Biopharm's history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |